BIO Is Helping Companies Boost Minority Participation In Clinical Trials

BIO head Michelle McMurry-Heath discusses group’s efforts to increase enrollment of people of color in COVID-19 clinical trials and why New York’s task force to give second review to COVID-19 vaccines is “dangerous for patients.”

BIO President and CEO Michelle McMurray-Heath
BIO President & CEO Michelle McMurry-Heath • Source: Screenshot from FDLI annual conference

As COVID-19 vaccine makers have struggled to enroll minority populations in clinical trials, the Biotechnology Innovation Organization has stepped up to offer assistance.

“We’re trying with brute force to help our companies that are working on COVID trials for therapeutics and for vaccines...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D